Le Lézard
Classified in: Health
Subject: FDA

TECHLAB Receives FDA 510(k) Clearance To Market H. PYLORI QUIK CHEKtm And H. PYLORI CHEKtm Tests


BLACKSBURG, Va., Aug. 21, 2018 /PRNewswire/ -- TECHLAB, Inc., a leading developer and manufacturer of rapid non-invasive diagnostic tests for gastrointestinal diseases, today announced that it received U.S. Food and Drug Administration (FDA) clearance for the H. PYLORI QUIK CHEKtm and the H. PYLORI CHEKtm tests. Both are designed to aid in the diagnosis of H. pylori infection, a disease which affects half the population of the world.1  The disease is responsible for most duodenal and gastric ulcers and is associated with a two to three fold increased risk of gastric cancer and mucosal associated-lymphoid-type lymphoma.2  The H. PYLORI QUIK CHEKtm test is a rapid diagnostic test that detects H. pylori in 30 minutes. The H. PYLORI CHEKtm test is a 96-well plate format diagnostic for laboratories testing large numbers of specimens and can be performed with or without automation in one hour. The H. PYLORI CHEKtm and H. PYLORI QUIK CHEKtm tests exhibit strong performance and offer flexible transport conditions including room temperature storage of specimens and the use of C&S and Cary Blair transport media to simplify sample collection for patients and physicians. 

Techlab_Logo

"Our tests were compared against histology and urease testing performed on biopsies collected during endoscopy as both an initial diagnostic and a test of cure. Both assays provide excellent clinical performance. We are proud of TECHLAB's quality diagnostic assays," said Dr. Joel Herbein, VP of Scientific Affairs at TECHLAB.

H. pylori has a seropositivity rate of 36 percent in the United States.1 For that reason, the American College of Gastroenterology recommends a test that detects current disease, such as stool antigen testing, rather than serology.  The H. PYLORI QUIK CHEKtm and H. PYLORI CHEKtm tests offer quick and reliable detection of H. pylori-specific antigen in human fecal specimens.3 

About TECHLAB®

TECHLAB, Inc. (www.techlab.com) has been a leading developer and manufacturer of intestinal diagnostics products in the United States for 28 years. The Company has a market-leading portfolio of diagnostic tests for enteric diseases caused by C. difficile, food-borne pathogens, and protozoan parasites. TECHLAB also manufactures diagnostic tests for intestinal inflammation. TECHLAB is headquartered in Blacksburg, Va. and manufactures its diagnostic tests in the United States at its state-of-the-art manufacturing facility in Radford, Va.

References

  1. Talley N. 2005. AGA Medical Position Statement: Evaluation of dyspepsia. Gastroenterology 129:1753-1755.
  2. Burkitt MD, Duckworth CA, Williams JM, Pritchard DM. 2017. Helicobacter pylori-induced gastric pathology: insights from in vivo and ex vivo models. Disease Models & Mechanisms 10:89-104.
  3. Chey WD, Leontiadis GI, Howden CW, Moss SF. 2017. ACG Clinical Guideline: Treatment of Helicobacter pylori, Infection Am J Gastroenterol 112:212-238.

 

SOURCE TECHLAB, Inc.


These press releases may also interest you

at 17:20
Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on March 28, 2024. One individual was...

at 17:15
Paladin Labs Inc., a subsidiary of Endo International plc , today announced Health Canada's approval of WAKIX® (pitolisant hydrochloride tablets) for the treatment of excessive daytime sleepiness (EDS) or cataplexy in pediatric patients aged 6 years...

at 17:05
Sirona Biochem Corp. ("Sirona") announces the voting results from its Annual General Meeting of Shareholders (the "Meeting"), held in Vancouver, British Columbia on March 28, 2024. The total number of shares represented by shareholders present in...

at 17:00
The Doctors Company, the nation's largest physician-owned medical malpractice insurer, announced today that it has approved a 2024 premium dividend of approximately $14.7 million, bringing the total of declared dividends to date to $470 million....

at 17:00
Northern Virginia Oral, Maxillofacial & Implant Surgery ("NOVA OMS") has learned of a data security incident that may have impacted data belonging to certain patients and guarantors. On October 5, 2023, NOVA OMS became aware of unusual activity on...

at 17:00
The Journey Venture Studio announced today a strategic collaboration with Valleywise Health, a comprehensive healthcare system with locations throughout the Phoenix metro area. In pursuit of fostering innovation, this collaboration is set to...



News published on and distributed by: